Sugi Predict

Sugi Predict / Compounds / SCHEMBL33777

SCHEMBL33777

SCHEMBL33777

CC(=O)OC1/C=C/C(C)(O)C(=O)C(C)C/C=C\C2C(O)C(C)=C(C)C3C(Cc4ccccc4)NC(=O)C123

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NR0B1 P51843 1/20 0.74
▸ ADORA3 P0DMS8 1/20 0.58
▸ CCR5 P51681 1/20 0.49
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ NPC1 O15118 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ SLC2A1 P11166 1/20 0.34
▸ SLC2A2 P11168 1/20 0.34
▸ SLC2A3 P11169 1/20 0.34
▸ SLC2A4 P14672 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ SLC2A9 Q9NRM0 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ HIF1A Q16665 1/20 0.34
▸ PAX8 Q06710 1/20 0.34
▸ CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cytochalasin D SCHEMBL33529 0.85 NR0B1 (1.00) NR0B1ADORA3CCR5MEN1KMT2A
Cytochalasin D SCHEMBL16502284 0.85 NR0B1 (1.00) NR0B1ADORA3CCR5MEN1KMT2A
Cytochalasin D SCHEMBL29375699 0.85 NR0B1 (1.00) NR0B1ADORA3CCR5MEN1KMT2A
Cytochalasin D SCHEMBL25847004 0.85 NR0B1 (1.00) NR0B1ADORA3CCR5MEN1KMT2A
Cytochalasin D SCHEMBL31734099 0.85 NR0B1 (1.00) NR0B1ADORA3CCR5MEN1KMT2A
Cytochalasin D SCHEMBL12648577 0.85 NR0B1 (1.00) NR0B1ADORA3CCR5MEN1KMT2A
Cytochalasin D SCHEMBL33528 0.85 NR0B1 (1.00) NR0B1ADORA3CCR5MEN1KMT2A
SCHEMBL14646636 0.85 NR0B1 (0.77) NR0B1ADORA3CCR5MEN1KMT2A
SCHEMBL29515454 0.82 CCR5 (0.71) NR0B1ADORA3CCR5MEN1KMT2A
SCHEMBL29745878 0.81 NR0B1 (0.86) NR0B1ADORA3CCR5MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119020288-A Migration body and use thereof 北京迈格松生物科技有限公司 2024-11-26 — — CN claimed
CN-118980754-A Method for detecting 62 mycotoxins in spice 广西—东盟食品检验检测中心 2024-11-19 — — CN claimed
EP-4438719-A1 ENGINEERED MIGRATION BODY, AND PREPARATION METHOD THEREFOR AND USE THEREOF Beijing Migrasome Therapeutics Limited (CN) 2024-10-02 — — EP claimed
CN-116964192-A Engineered migrates and methods of making and using same 北京迈格松生物科技有限公司 2023-10-27 — — CN claimed
CN-110863021-B Preparation method and application of cytochalasin compound 广西师范大学 2023-06-16 — — CN claimed
CN-110551682-B Kit and method for dissociation of animal embryos 深圳华大生命科学研究院 2023-06-09 — — CN claimed
WO-2023093780-A1 ENGINEERED MIGRATION BODY, AND PREPARATION METHOD THEREFOR AND USE THEREOF 北京迈格松生物科技有限公司 2023-06-01 — — WO claimed
CN-116162595-A Engineered migrates and methods of making and using same 北京迈格松生物科技有限公司 2023-05-26 — — CN claimed
CN-111808015-B Phenylalanine-derived cytochalasin as well as preparation method and application thereof 兰州大学 2022-04-26 — — CN claimed
EP-2919795-B1 SOLUBILIZATION OF ANTIGEN COMPONENTS FOR REMOVAL FROM TISSUES UNIV CALIFORNIA (US) 2021-06-30 — — EP claimed
CN-100497598-C Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues UNIV MASSACHUSETTS (US) 2009-06-10 — — CN claimed
US-20090143279-A1 Methods and compositions for treating metabolic disorders PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2009-06-04 — — US claimed
US-20090062904-A1 STENT COATING ICON INTERVENTIONAL SYSTEMS, INC. 2009-03-05 — — US claimed
WO-2008156654-A2 CYTOSKELETON MODULATORS FOR TREATING METABOLIC DISORDERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2008-12-24 — — WO claimed
US-20020013275-A1 Therapeutic inhibitor of vascular smooth muscle cells NEORX CORPORATION 2002-01-31 — — US claimed
EP-0681475-A4 THERAPEUTIC INHIBITORS OF VASCULAR SMOOTH MUSCLE CELLS NEORX CORP (US) 2000-01-05 — — EP claimed
US-5994388-A Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 1999-11-30 — — US claimed
WO-1998041205-A1 CYTOCHALASIN AND ISOINDOLINONE DERIVATIVES AS INHIBITORS OF ANGIOGENESIS THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 1998-09-24 — — WO claimed
EP-0681475-A1 THERAPEUTIC INHIBITORS OF VASCULAR SMOOTH MUSCLE CELLS NEORX CORPORATION (US) 1995-11-15 — — EP claimed
WO-1994016706-A1 THERAPEUTIC INHIBITORS OF VASCULAR SMOOTH MUSCLE CELLS NEORX CORPORATION (US) 1994-08-04 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013275-A1 Therapeutic inhibitor of vascular smooth muscle cells MYLK, VCAM1, MYLK2 NR0B1 3037/4885ADORA3 4662/4885CCR5 1417/4885
US-20090143279-A1 Methods and compositions for treating metabolic disorders PC, PCK2, CS NR0B1 3104/4885ADORA3 2528/4885CCR5 4779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.